Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan’s MHLW And Baxter In Talks To Bring New Flu Vaccines To Japan

This article was originally published in PharmAsia News

Executive Summary

U.S. major drug maker Baxter International June 16 disclosed that the company is talking with Japan's Ministry of Health, Labor and Welfare about exporting new H1N1 flu vaccines to Japan. Baxter said a negotiation toward signing a supply contract with the MHLW is ongoing and the first shipment could be ready as early as July. Currently, four Japanese domestic vaccine makers including Kitazato Institute are preparing to manufacture flu vaccines for the new H1N1 flu virus; however, due to limited production capability, the MHLW has been actively looking for additional supplies from overseas vaccine makers. Using cell engineering technology rather than the conventional egg method, Baxter is capable of producing a large amount of H1N1 vaccine in a shorter period of time. Baxter plans a July shipment, and could supply the world's first H1N1 vaccines ahead of Novartis. (Click here for more - Japanese Language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071925

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel